Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
In summary, risk score based on circulating sCTLA-4 and sCD74 reflects the response to immune checkpoint inhibitor (ICI) therapy in MM patients. If confirmed, through further validation, these findings could assist in recommending therapy to patients likely to experience a long-lasting response.
Authors
- Letizia Porcelli (ORCID: https://orcid.org/0000-0003-0175-9716)
- R. Fonte (ORCID: https://orcid.org/0000-0002-8541-686X)
- Simona De Summa (ORCID: https://orcid.org/0000-0001-9607-3754)
- Amalia Azzariti (ORCID: https://orcid.org/0000-0002-6149-5049)
- Rossella Fasano (ORCID: https://orcid.org/0000-0003-4123-7234)
- Michele Guida (ORCID: https://orcid.org/0000-0001-8411-0319)
- Ivana De Risi (ORCID: https://orcid.org/0000-0002-6330-797X)
- Sabino Strippoli (ORCID: https://orcid.org/0000-0001-7982-7788)
- Simona Serratì (ORCID: https://orcid.org/0000-0002-4015-5205)
- Tommaso Maria Marvulli (ORCID: https://orcid.org/0000-0001-9962-1955)
- Giuseppe De Palma (ORCID: https://orcid.org/0000-0002-6108-096X)
Institutions
- Istituto Tumori Bari (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1186/s13046-025-03306-w
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Ministero della Salute
- Regione Puglia